Plans for flat pharmacovigilance fee in EU should be out by Q2 end
This article was originally published in SRA
Executive Summary
Proposals that would see pharmaceutical companies in the EU pay the European Medicines Agency an annual flat fee to cover the agency’s responsibilities under the new EU pharmacovigilance legislation could see the light of day by the end of June1.